Death receptor-induced apoptosis is paradigmatically mediated via the recruitment of FADD adapter molecule to the ligand/receptor complex and subsequent activation of caspase-8. However, several observations provided evidence that components of the mitochondrial apoptosis pathway are involved in death receptor-mediated apoptosis. In this regard, caspase-8-mediated activation of Bid induces the release of cytochrome c from the mitochondria, which, in turn, triggers the formation of the apoptosome protein complex, resulting in the activation of caspase-9. Whereas Bax or Bak were shown to be required for the proapoptotic effect of Bid, Bcl-2 was described to interfere with its action. Up to now, contradictory results regarding the role of Bcl-2 in TRAIL-induced apoptosis have been published. In order to study the influence of Bcl-2 on TRAIL-induced cell death more detailed, we utilized a tetracycline-regulated Bcl-2 expression system in Jurkat T cells. After having analysed the dose response for TRAIL-induced activation of caspase-8, -9, -3, breakdown of the mitochondrial membrane potential, and changes in the apoptotic morphology in cells expressing different Bcl-2 levels, we conclude that overexpression of Bcl-2 mediates a partial resistance towards lower doses of TRAIL that can be overcome when higher doses of TRAIL are applied. Thus, the requirement of the mitochondrial pathway for death receptor-induced apoptosis in type II cells should be reconsidered, since the protective effect of Bcl-2 is limited to lower TRAIL doses or early observation time points.
Introduction
Receptor-induced apoptosis plays an important role in the maintenance of immune homeostasis, elimination of virus-infected cells, and tumour cells (Krammer et al., 1994; Takeda et al., 2001) .
Death receptors belong to the superfamily of tumour necrosis factor receptors (TNFR), which comprises the tumour necrosis factor receptor 1 (TNF-R1 or p55TNFR), CD95/Fas/Apo-1, the TNF-related apoptosis-inducing ligand receptors TRAIL-R1/DR4, and TRAIL-R2/DR5, as well as DR6. This receptor family is characterised by extracellular cysteine-rich domains, which are required for ligand binding and a cytosolic death domain (DD) that is essential for intracellular signal transduction as well as apoptosis induction.
The first death ligand/receptor system described was the TNFa/TNF-R1 system, which plays an important role for immunomodulation after infection by bacterial, fungal, and viral pathogens (Rothe et al., 1993; Erickson et al., 1994) . Stimulation of TNF-R1 or CD95/Fas/Apo-1, another well-characterized death receptor, by their cognate ligands TNFa or CD95L/FasL/Apo-1L induces apoptosis in several nonmalignant cell systems, as well as in tumour cells. The third important member of the death ligand family was identified by a low-stringency databank search employing the TNFa sequence as bait (Pitti et al., 1996) . The new ligand was named Apo-2-L or tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). To date, TRAIL is considered a highly promising candidate as tumoricidal drug, since it has been shown to induce apoptosis specifically in the malignant or transformed cell system, whereas it has no cytotoxic effect on nonmalignant cells (Ashkenazi et al., 1999; Walczak et al., 1999; Held and SchulzeOsthoff, 2001; Wajant et al., 2002; Belka et al., 2003a) . However, the initial exaltation was alleviated after it had become evident that high-order complexes of the TRAIL molecule do induce apoptosis in primary liver cells ex vivo (Jo et al., 2000; Nagata, 2000; Lawrence et al., 2001) .
In contrast to CD95L and TNFa, TRAIL can trigger apoptosis via two different receptors, namely TRAIL-R1/DR4 and TRAIL-R2/DR5. Additionally, there are two truncated TRAIL receptors, TRAIL-R3/DcR1 and TRAIL-R4/DcR2, which lack an intact death domain and therefore are not able to transduce the death signal to the cytosol. By competition with the agonistic receptors, these 'decoy receptors' reduce the sensitivity of cells to TRAIL-induced apoptosis (Sheridan et al., 1997) .
The intracellular signal transduction cascades triggered by the three death ligands follow similar pathways. Binding of the trimeric or multimeric ligands to their respective receptors results in receptor activation. Previous studies have shown that receptor trimerization or oligomerization is essential for their activation, but recent analyses revealed a ligand-independent preclustering in form of homotrimers for TNF-R1 and CD95. Following ligand binding, procaspase-8 and -10 are recruited to the receptor-ligand complex via the adapter protein Fas-associated protein with death domain (FADD), leading to the assembly of a protein complex called death-inducing signalling complex (DISC) (Chinnaiyan et al., 1995; Muzio et al., 1996; Kischkel et al., 2001) . According to the inducedproximity model, the clustering of procaspases in the complex is sufficient for their initial activation (Salvesen and Dixit, 1997; Muzio et al., 1998) . Subsequently, caspase-8 and probably also caspase-10 activate the downstream effector caspases, for example, caspase-3, by proteolytic processing . Once the caspase cascade is activated, the downstream caspases cleave various structure and repair proteins, resulting in the final morphological changes associated with apoptosis (Fischer et al., 2003) .
This apoptotic pathway initiated by ligands is complemented by a second death pathway, the so-called mitochondrial or intrinsic pathway, which is initiated by the release of cytochrome c from the mitochondria into the cytosol. Cytosolic cytochrome c triggers the energydependent oligomerization of the adapter protein apoptosis-activating factor-1 (Apaf-1), leading to the recruitment of procaspase-9, thus, forming a large multimeric protein cluster comparable to the DISC in the death receptor-dependent pathway (Li et al., 1997; Saleh et al., 1999) . Here again, clustering of the procaspase is responsible for its activation. In its activated form, caspase-9, like caspase-8, is able to trigger the downstream caspase cascade, finally leading to apoptosis.
The two signalling cascades are connected via the proapoptotic Bcl-2 family member Bid (Wang et al., 1996) , a substrate of activated caspase-8 and -3 (Wang et al., 1996; Li et al., 1998; Luo et al., 1998; Yin et al., 1999; Degli Esposti et al., 2003) . In its truncated form (tBid), Bid translocates from the cytosol to the mitochondria and triggers in cooperation with Bax or Bak, two other proapoptotic Bcl-2 family members, cytochrome c release, and the breakdown of mitochondrial membrane potential (Wang et al., 1996; Li et al., 1998; Luo et al., 1998; Yin et al., 1999) . Though well known for years, the detailed mechanisms controlling cytochrome c release are still under consideration. So far, it is known that the members of the Bcl-2 family are crucial players in this scenario (Guner et al., 2003) . The proapoptotic members like Bax and Bak promote cytochrome c release, whereas the antiapoptotic members like Bcl-2 and Bcl-x L inhibit it (Kluck et al., 1997; Belka and Budach, 2002; Rudner et al., 2002) . However, the involvement of the Bcl-2 family members and the mitochondrial pathway in death receptor-triggered apoptosis has been discussed controversially for the last few years (Strasser et al., 1995; Weller et al., 1995; Medema et al., 1998; Schmitz et al., 1999; Belka et al., 2000 Belka et al., , 2001 Belka et al., , 2003b Hinz et al., 2000; Huang et al., 2000; Walczak et al., 2000; de Almodovar et al., 2001; Suliman et al., 2001; Sun et al., 2001 Sun et al., , 2002a Zhang et al., 2001; Fulda et al., 2002; Velthuis et al., 2002) . Regarding the CD95 receptor-ligand system, Scaffidi et al. (1998) introduced the model of type I and type II cells. In the so-called type I cells (e.g. SKW6.4 and H9 cells) caspase-3 becomes directly activated by caspase-8, whereas in type II cells (e.g. CEM and Jurkat cells) caspase-3 activation involves activation of caspase-9 through the mitochondrial pathway. Thus, blocking the mitochondrial breakdown and cytochrome c release by overexpression of the antiapoptotic protein Bcl-2 or a related member of this protein family abrogates CD95L-induced apoptosis in type II cells, but does not interfere with CD95L-mediated apoptosis induction in type I cells.
The Jurkat T-cell lymphoma cell line was originally classified as a type II cell line, since Bcl-2 overexpression blocked apoptosis induced by CD95 (Scaffidi et al., , 1999 . Several other groups provided evidence for an influence of Bcl-2 or related antiapoptotic molecules on CD95-induced cell death in various cell systems (Weller et al., 1995; Medema et al., 1998; Sun et al., 2002b) . In contrast, we and other groups have shown that Bcl-2 overexpression does not interfere with CD95-induced apoptosis in Jurkat and other cell systems, whereas Bcl-2 and Bcl-x L were able to inhibit apoptosis in response to cytotoxic drugs and ionizing radiation (Strasser et al., 1995; Belka et al., 1999 Belka et al., , 2000 Huang et al., 1999 Huang et al., , 2000 Engels et al., 2000; Rudner et al., 2001) .
Similar results were obtained when cells were treated with TRAIL: Several groups did not observe a Bcl-2-mediated resistance towards TRAIL-induced cell death (Gazitt, 1999; Keogh et al., 2000; Walczak et al., 2000; Belka et al., 2001 Belka et al., , 2003b Rudner et al., 2001; Velthuis et al., 2002) , whereas in various other studies Bcl-2 expression rendered cells resistant towards TRAILinduced apoptosis (Hinz et al., 2000; de Almodovar et al., 2001; Sun et al., 2001; Fulda et al., 2002; Johnson et al., 2003; Kim et al., 2003 Kim et al., , 2004 Lacour et al., 2003; Zhang et al., 2003) .
In order to study the influence of Bcl-2 on TRAILinduced cell death in more detail, we employed a tetracycline-regulated Bcl-2 expression system in Jurkat T cells. To study the dose response of TRAIL-induced apoptosis, TRAIL-induced activation of caspase-8, -9, -3, the breakdown of the mitochondrial membrane potential, and apoptosis were studied at multiple time points, dose levels of TRAIL, and different Bcl-2 expression levels.
The use of a regulated expression system eliminates possible influences resulting from a selection process during the establishment of cells and cell clones stably expressing Bcl-2. In addition, the tetracycline-repression (Tet-off) system provides us with a tool for a finely tuned titration of cellular Bcl-2 expression levels.
Our data suggest a complex relationship between the strength of the initial death trigger, the time point of apoptosis determination, and the expression level of Bcl-2 in TRAIL-induced apoptosis.
Results

Repression of Bcl-2 expression
In order to study the influence of Bcl-2 on TRAILinduced cell death, we generated a Jurkat T-cell line expressing Bcl-2 under the control of a tetracyclinerepressed promoter. As a proof of principle, Bcl-2 expression was determined by Western blot analysis after daily treatment of cells with doxycycline over 3 days. Whereas high levels of Bcl-2 expression could be detected in untreated cells, the Bcl-2 expression was almost abrogated in cells treated with doxycycline ( Figure 1 ). The baseline expression of endogenous Bcl-2 in Jurkat cells is responsible for the weak expression level seen in doxycycline-treated cells, since it was also found in nontransfected counterparts. Thus, treatment with doxycycline for 3 days is sufficient to repress Bcl-2 expression.
Effect of Bcl-2 on dose-dependent apoptosis induction
To determine the influence of Bcl-2 on TRAIL-induced apoptosis, unrepressed and doxycycline-repressed Jurkat Bcl-2 Tet-off (Jurkat Bcl-2) and vector Tet-off control cells (Jurkat vector) were stimulated with different doses of TRAIL ranging from 0.025 to 25 ng/ ml. At 24 h after stimulation, apoptosis was quantified by flow cytometric analysis using forward/sideward scatter characteristics.
Substantial differences could be observed when comparing the dose responses of doxycycline-treated and untreated Jurkat cells (Figure 2a ). Bcl-2-expressing cells were completely resistant to TRAIL doses lower than 1 ng/ml in all the five independent experiments. However, they became susceptible to apoptosis induction when higher doses of TRAIL were applied.
In the vector control cells, apoptosis induction was dose-dependent with minimal apoptosis induction at 0.25 ng/ml and maximal apoptosis at B10 ng/ml TRAIL. No significant differences in the levels of apoptosis induction could be observed in the presence or absence of doxycycline, implying that doxycycline itself does not have an influence on the exogenous death program ( Figure 2a ).
As shown in Figure 2b , apoptosis induction was attenuated but not abrogated in cells expressing Bcl-2 when intermediate TRAIL doses were applied. The most prominent protective effect of Bcl-2 was observed at doses ranging from 1 to 10 ng/ml TRAIL. Bcl-2 protection was overcome after stimulation with higher TRAIL doses.
Effect of Bcl-2 on dose-dependent caspase activation
As described above, caspase activation is a crucial step of the exogenous suicide program. During TRAILinduced apoptosis, caspase-8 is initially activated after the recruitment to the receptor complex DISC. The two isoforms of procaspase-8 (a/b), 54/52 kDa in size, are cleaved into intermediate products of p43/41 kDa prior to further cleavage between the large and small subunits. Caspase-9 can be activated through the mitochondrial pathway at the apoptosome after the release of cytochrome c from mitochondrial intermembrane space. The fragment generated by autoproteolysis is about B37 kDa in size, whereas caspase-3-dependent cleavage results in an active Bp35 fragment form. In addition, caspase-3 (p32) can be activated either by caspase-8, -9, or by itself by autoproteolysis.
To define the influence of Bcl-2 on TRAIL-induced apoptosis more precisely, the processing of the relevant caspases (caspase-8, -9, -3) as well as of the caspase-3 substrate poly ADP ribosyl polymerase (PARP) was determined by Western blot analysis. As shown in Figure 3 , 4 h after TRAIL stimulation proteolytic processing of the examined caspases and PARP occurred in a dose-dependent manner. Expression of Bcl-2 clearly reduced the extent of caspase processing, whereas no difference was detectable in the vector control cells treated with or without the repressing doxycycline. Additionally, Bcl-2 blocked caspase and PARP cleavage only at lower concentrations, but lost the inhibitory effect when higher concentrations of TRAIL were applied (Figure 3) . The detailed comparison of the caspase-processing patterns in terms of cleavage products revealed no significant differences.
In the absence of Bcl-2 expression, caspase-8 cleavage was detectable after stimulation with 0.1 ng/ml TRAIL (4 h), whereas in cells expressing Bcl-2 caspase-8 was not found to be activated at any dose below 1 ng/ml TRAIL (4 h). In accordance, the p35 fragment of activated Lower panel: After treatment with Dox (1.5 mg/ml) at the indicated time points (72, 48, 24 h), the expression level of Bcl-2 is reduced to background levels Bcl-2 in TRAIL-induced apoptosis J Rudner et al caspase-9 was detectable after stimulation with TRAIL in the absence of Bcl-2, whereas doses above 2.5 ng/ml were required for caspase-9 processing in Bcl-2-expressing cells. Similar results were obtained when the consumption of the proform of caspase-8 or -3 is taken into account: 4 h after TRAIL stimulation (10, 25, and 100 ng/ml), the proforms of caspase-8 and -3 were merely detectable in the absence of Bcl-2, whereas in Processing of caspase-8 (casp8), caspase-9 (casp9 active fragment), caspase-3 (casp3), and PARP 4 h after stimulation with (from left to right) 0 ng/ml TRAIL (0), 0.0025 ng/ml TRAIL, 0.1 ng/ml TRAIL, 0.25 ng/ml TRAIL, 1 ng/ml TRAIL, 2.5 ng/ml TRAIL, 10 ng/ml TRAIL, 25 ng/ml TRAIL, and 100 ng/ml TRAIL in Bcl-2 cells in the presence of Bcl-2 ( þ Bcl-2) and after suppression of Bcl-2 (ÀBcl-2). Right panel: Processing of caspase-8 (casp8), caspase-9 (casp9 active fragment), caspase-3 (casp3), and PARP 4 h after stimulation with (from left to right) 0 ng/ml TRAIL, 0.0025 ng/ml TRAIL, 0.1 ng/ml TRAIL, 0.25 ng/ml TRAIL, 1 ng/ml TRAIL, 2.5 ng/ml TRAIL, 10 ng/ml TRAIL, 25 ng/ml TRAIL, and 100 ng/ml TRAIL in vector control cells in the presence and absence of doxycycline (7dox)
Bcl-2 in TRAIL-induced apoptosis J Rudner et al cells expressing Bcl-2 the proforms remained visible. In addition, the kinetics of PARP cleavage exactly reflected the processing of caspase-3.
Effect of Bcl-2 on the kinetics of TRAIL-induced apoptosis
Our data indicate that Bcl-2 overexpression induces a partial resistance in Jurkat cells when apoptosis and caspase processing are measured at early time points. In order to further clarify the impact of Bcl-2 on TRAILinduced cell death, the time and dose relationships were determined over a prolonged time period. As shown in Figure 4 , the partial resistance of Bcl-2-overexpressing cells towards TRAIL-induced apoptosis was sustained over a period of 48 h when doses between 1 and 10 ng/ml were applied. When stimulated with 25 ng/ml TRAIL, apoptosis induction occurred with similar kinetics in doxycycline-treated (Bcl-2 expression suppressed) and untreated cells (Bcl-2 expression switched on). The most pronounced difference between Bcl-2-overexpressing cells and their repressed counterparts was detectable after treatment with 0.25, 1, or 2.5 ng/ml TRAIL (see Figure 4b ).
Effect of Bcl-2 on time course of caspase cleavage
To examine whether the caspase cleavage patterns correspond to the Bcl-2-mediated survival benefit in response to intermediate doses of TRAIL, cells were stimulated with either 0.25 or 25 ng/ml TRAIL and proteolytic processing of caspase-8, -9, -3 and PARP was determined at different time points. As shown in Figure 5 , Bcl-2 delayed the cleavage of the respective caspases when cells were stimulated with 25 ng/ml TRAIL. This delaying effect on caspase cleavage was even more pronounced when lower doses of TRAIL (0.25 ng/ml TRAIL) were applied. Taken together, our data indicate that the partial protection of Bcl-2 towards TRAIL-induced apoptosis depends on the strength and the duration of the initial stimulus. 
Effect of Bcl-2 expression level on apoptosis induction and caspase cleavage
To examine the partial protection towards TRAIL more closely, apoptosis was studied in cells in which the Bcl-2 expression was adjusted to different levels. As shown in Figure 6 , the degree of Bcl-2 repression was clearly dependent on the duration of doxycycline incubation (Figure 6a ). The longer the cells were incubated in doxycycline-supplemented medium, the lower was the Bcl-2 expression level, reaching background levels after 3 days. Therefore, Jurkat Bcl-2 cells were incubated in doxycycline-containing medium for different time periods prior to stimulation with TRAIL ( Figure 6b ). As shown in Figure 7a , apoptosis induction by intermediate doses of TRAIL (1 and 2.5 ng/ml TRAIL) was attenuated with increasing Bcl-2 levels. Only marginal effects were detectable when cells were stimulated with maximal doses of TRAIL (25 ng/ml). Moreover, after treatment with 1 or 2.5 ng/ml TRAIL, the extent of protection was enhanced in the case of increased amounts of Bcl-2 (Figure 7a and b) . As expected, apoptosis induction was not significantly affected by the Bcl-2 expression when high doses of TRAIL (25 ng/ml) were applied. These data were confirmed by analysis of caspase-8, -9, -3, and PARP cleavage 4 h after treatment with TRAIL ( Figure 8 ). With increasing Bcl-2 levels, the processing of caspase-8, -9, and -3 was reduced more potently when cells were stimulated with TRAIL at lower concentrations, that is, at 1 or 2.5 ng/ml. However, when the cells were treated with 25 ng/ml TRAIL, no apparent differences in caspase processing could be detected, irrespective of the Bcl-2 expression level. The same conclusions could be drawn from studying the PARP cleavage. Altogether, these data indicate that both the level of Bcl-2 expression and the extent of receptor triggering determine whether Jurkat cells behave like type I or type II cells.
Discussion
In the last few years, a lot of conflicting data regarding the role of Bcl-2 in death receptor-mediated apoptosis have been provided. Whereas several studies clearly stated that Bcl-2 has no detectable influence on receptormediated cell death, other investigators came to the Figure 5 Influence of Bcl-2 on the dose and time-response relationships of TRAIL-induced caspase activation: Left panel: Processing of caspase-8 (casp8), caspase-9 (casp9 active fragment), caspase-3 (casp3), and PARP 2, 4, 6, 12, and 24 h after stimulation with 0.25 ng/ml TRAIL or 1, 2, 4, and 6 h after stimulation with 25 ng/ml TRAIL in Bcl-2 cells in the presence of Bcl-2 ( þ Bcl-2) and after suppression of Bcl-2 (ÀBcl-2). Right panel: Processing of caspase-8 (casp8), caspase-9 (casp9 active fragment), caspase-3 (casp3), and PARP 2, 4, 6, 12, and 24 h after stimulation with 0.25 ng/ml TRAIL or 1, 2, 4, and 6 h after stimulation with 25 ng/ml TRAIL in vector control cells in the presence and absence of doxycycline (7dox) Bcl-2 in TRAIL-induced apoptosis J Rudner et al conclusion that Bcl-2 obviously interferes with death receptor-mediated apoptosis. It is of special importance to notice that several groups have drawn mutually contradictory conclusions although having used the same cell systems Sun et al., 2002a) . To track down the problems leading to these obvious discrepancies, we used a Tet-repressed Bcl-2 expression system to determine the dose-response relationships for TRAIL-induced apoptosis over a wide range of time points and protein expression levels of Bcl-2. In addition to the possibility to adjust the Bcl-2 expression to different levels, the Tet-off system enabled us to minimize any potential effects associated with genetic alterations during clonal selection.
Bcl-2-mediated inhibition of death receptor-induced apoptosis is complex
Our data point to a complex relationship between Bcl-2-mediated inhibition of apoptosis and the protein expression level, the strength, and the duration of the death receptor stimulus. In the case of a weak stimulus and a short stimulation time, Bcl-2 conferred an apparent resistance towards death receptor stimulation by TRAIL, though such protection was not detectable when high doses of the death-inducing ligand were applied. In this case, only a marginal but insignificant delay in apoptosis induction could be observed. In addition, we showed that the inhibition of apoptosis was enhanced with increasing Bcl-2 expression level. This finding confirms previous experiments in MCF-7 cells by Ruiz de , who demonstrated an increased Bcl-2-mediated resistance towards TRAIL with higher Bcl-2 expression levels.
The model of type I and type II cells
With respect of the involvement of the mitochondrial death pathway in CD95-mediated apoptosis, Scaffidi et al. (1998) introduced the model of type I (SKW6.4, H9) and type II cells (Jurkat and CEM) according to the interfering role of Bcl-2. In the former cell type, Bcl-2 did not block cytochrome c release, whereas in the latter it had a strong protective effect. In a more elaborate version of this model, it was suggested that the initial formation of the signalling complex DISC and subsequent caspase-8 activation was not sufficient to activate the effector caspase-3, but adequate for the cleavage of the proapoptotic molecule Bid, which consequently translocated to the mitochondria to promote cytochrome c release in cooperation with Bak or Bax (Cheng et al., 2001) . Bcl-2 interferes with this process by heterodimerizing with Bid, Bax or Bak (Cheng et al., 2001) , or other mechanisms (Ruffolo and Shore, 2003; Yi et al., 2003) , thereby maintaining mitochondrial homeostasis. A new facet of this model was introduced with the discovery of Smac/Diablo, another mitochondrial protein, whose release from the intermembrane space during apoptosis induction is promoted by the proapoptotic Bcl-2 family members Bid, Bax, and Bak, and is blocked by the antiapoptotic (Sun et al., 2002b) . Once in the cytosol, Smac/Diablo interacts with members of the IAP family, thereby releasing caspase-9, -3, and -7 from the inhibitory complex with the IAPs. These events leading to the terminal apoptosis onset upon exposure to TRAIL were intercepted by overexpression of Bcl-2 or the lack of functional Bax or Bak protein (Sun et al., 2002b) . According to such a model, it was shown that death receptor-induced apoptosis was strongly reduced in Jurkat cells overexpressing Bcl-2 or Bcl-x L . Furthermore, less Smac/Diablo was released from the mitochondria and the processing of caspase-8 and -3 was strongly attenuated. The authors concluded that aside from Bcl-2 expression levels the ratio of XIAP to Smac/ Diablo may affect the behaviour as type I or type II cells, and that not the release of cyctochrome c but rather the release of Smac is the crucial Bcl-2-inhibitable step in type II cells. However, our data clearly demonstrate that Bcl-2-mediated protection in the assumed type II Jurkat cell line is only seen under special circumstances, that is, when lower TRAIL concentrations were employed. This delineates the existence of a transitional state between type I and type II for some cells. Following even the lowest doses of TRAIL (0.25 ng/ml), a minimal and delayed activation of caspase-8 could be detected in Bcl-2-expressing cells. However, the initial signal is not strong enough to activate downstream caspases, which may increase the activation of caspase-8 via the described mitochondrial feedback loop. Thus, in case of a very weak signal, the mitochondrial amplification is of crucial importance for the adequate propagation of the death signal (Figure 9b ). In contrast, stimulation with higher doses of TRAIL results in apoptosis induction through direct effector caspase activation not requiring the mitochondrial pathway ( Figure 9a ).
Different experimental setups, ligand preparations, and agonistic antibodies
The partial protection of Bcl-2 in receptor-mediated cell death presented here does not contradict precedent in vivo findings, which demonstrated either the absolute requirement or the exclusion of the mitochondrial pathway depending on the examined cell type. In this regard, it has been shown that primary hepatocytes expressing Bcl-2 are mostly refractory to CD95L-induced apoptosis even when stimulated with high doses (Rodriguez et al., 1996) , whereas activated T cells undergo apoptosis regardless of Bcl-2 expression (Strasser et al., 1995) . These apparently contradictory results may, however, be explained when the different experimental procedures are analysed more closely. Most of the data regarding the influence of Bcl-2 on death receptor-mediated cell death were acquired using agonistic antibodies against the CD95 receptor or recombinant soluble death ligands. Yet, it remains unclear how far antibody stimulation reflects the physiological situation, since such antibodies may differ in their ability to crosslink the respective death receptors (Dhein et al., 1995) . The majority of recombinant soluble ligands applied in previous experiments are either synthesized as tagged molecules requiring a secondary crosslinking antibody in order to be fully active, or are fused to a leucine zipper domain that facilitates crosslinking. To reduce these potential influences, we have therefore used a soluble recombinant TRAIL without any modification, Bcl-2 in TRAIL-induced apoptosis J Rudner et al which crosslinks the receptors independently of any secondary crosslinkers or protein tags and, thus, mimics the in vivo situation very well. Furthermore, the use of TRAIL should be favoured over CD95-L, since a recent observation suggested that, in contrast to soluble CD95-L (Holler et al., 2003) , soluble TRAIL is physiologically active in vivo (Tecchio et al., 2004) . However, it remains to be resolved which level of TRAIL stimulation reflects best the physiological situation. Since TRAIL effects are usually mediated by cell-cell contacts, local concentrations may reach high levels.
Taken together, our findings implicate a variable protection by Bcl-2 in TRAIL-induced apoptosis, depending on its expression levels, the strength, and duration of the stimulus. In contrast, the activation of the mitochondrial pathway seems to be a conditio sine qua none in stress-mediated and endogenous cell death induction (von Haefen et al., 2002; Belka et al., 2003b; Jendrossek et al., 2003a, b; Prokop et al., 2003) .
Alternative pathways triggered by TRAIL
Nevertheless, the contribution of Bcl-2 to cancer formation by inhibiting death ligand-induced apoptosis remains in the dark. Recent data established that TRAIL may activate other pathways apart from apoptosis (Mills et al., 2004) . Using MCF-10A cells to study lumen formation in a 3D cell culture model, the group demonstrated that TRAIL stimulation induced not only apoptosis but also autophagy. The death ligand, which is upregulated during the MCF-10A morphogenesis, seems to trigger cell death forming the lumen inside the cell colonies through both pathways. Blocking TRAIL signalling at the receptor level does not affect lumen formation, whereas inhibition at the mitochondrial level by overexpressing Bcl-x L does. Additionally, the interference at both levels leads to a reduction of colonies with intact cavities. These results indicate that only the deregulation of both pathways at different levels leads to abnormal morphogenesis. It is quite obvious that the interference with only one pathway is not able to control tumorigenesis and that tumour therapy could only be successful if several pathways were targeted, all at the same time. The combination of TRAIL with classical anticancer treatment strategies including radiation would therefore be of high value for a better elimination of clonogenic tumour cells. In this regard, it was already shown that TRAIL and radiation may cooperate synergistically in tumour cell eradication even when the mitochondrial pathway is blocked by Bcl-2 overexpression Marini et al., 2003; Weinmann et al., 2004) .
Materials and methods
Reagents and antibodies
All chemicals were purchased from Sigma (Deisenhofen, Germany) unless otherwise specified. Monoclonal antibody against Bcl-2 from Santa Cruz Biotechnology (Heidelberg, Germany) was used as a 1 : 2000 dilution. Murine monoclonal antibody against caspase-8 was kindly provided by K SchulzeOsthoff, and was used as 1 : 50 dilution of hybridoma cell supernatant. Rabbit antibodies against active caspase-9 (p35), active caspase-3, and PARP were obtained from Cell Signalling Technology (NEB Frankfurt, Germany) and used at 1 : 1000 dilutions. Monoclonal antibody against caspase-3 from Transduction Laboratories (BD Heidelberg, Germany) was used as a 1 : 1000 dilution. HRP-conjugated anti-mouse and anti-rabbit antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, Heidelberg, Germany). These secondary antibodies were used as 1 : 20 000 dilutions. Figure 9 Model of the Bcl-2-mediated inhibition of TRAILinduced apoptosis: (a) High dose of TRAIL or long incubation period. The death receptor signal is strong enough for direct effector caspase activation and the mitochondrial pathway is not essentially required. Hence, Bcl-2 overexpression does not exert any protective effect. (The key pathway is indicated by a solid black line, the minor pathway by a dotted grey line.) (b) Low dose of TRAIL or short incubation period. Owing to the weak death receptor signal, the mitochondrial amplification is of crucial importance for the adequate propagation of the apoptosis signal. Accordingly, in this case, Bcl-2 overexpression can inhibit TRAILinduced apoptosis (the key pathway is indicated by a solid black line, the minor pathway by a dotted grey line)
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Cell culture and transfection
Cells were maintained in RPMI 1640 (Gibco Life Technologies, Eggenstein, Germany) in a humidified incubator at 371C and 5% CO 2 . Jurkat T-cell lymphoma Tet-off cells were purchased from Clontech (Heidelberg). To generate inducible Bcl-2 transfectants, the human Bcl-2 open reading frame was cloned into pTRE2hyg vector (Clontech, Heidelberg, Germany). In all, 25 mg of the vector DNA was electroporated into Jurkat Tet-off cells at 125 mF and 500 V using a Gene pulser II electroporation device (BioRad, Munich, Germany). Transfected cells were selected with 250 mg/ml hygromycin B (Clontech, Heidelberg, Germany). To suppress Bcl-2 expression, Bcl-2 transfectants were treated with 1.5 mg/ml doxycycline (Clontech, Heidelberg, Germany) for at least 4 days. As control cells, the maternal Jurkat Tet-off cells were used.
Apoptosis induction and determination
Apoptosis was induced using the death ligand TRAIL (R&D Systems, Bad Nauheim, Germany) at indicated concentrations and quantified by analysing the forward and sideward scatter characteristics using a FACS Calibur flow cytometer (Becton Dickinson, Heidelberg, Germany).
Western blot analysis
Caspase cleavage was detected by Western blotting. In brief, 5 Â 10 6 cells were lysed with a buffer containing 25 mM HEPES, 0.1% SDS, 0.5% deoxycholate, 1% Triton X-100, 10 mM EDTA, 10 mM NaF, 125 mM NaCl, 20 mg/ml aprotinin, and 20 mg/ml leupeptin. Insoluble material was removed by centrifugation for 15 min at 10 000 g. The protein concentration was determined by BioRad protein assay (BioRad, Munich, Germany). Lysat (20 mg) was separated by SDS-PAGE and transferred onto a PVDF membrane (BioRad, Munich, Germany). Equal blotting was verified by Ponceau S staining (Sigma, Deisenhofen, Germany). After blocking the membrane with TBS buffer, pH 8.0, containing 0.05% Tween-20 and 5% FBS, the blot was incubated with the primary antibody at 41C overnight at the respective dilution. The membrane was washed three times with TBS/Tween-20 (0.05%) before incubating with the secondary antibody conjugated to horseradish peroxidase for 1 h at room temperature. After washing the membrane several times with TBS, binding of the secondary antibody was detected by enhanced chemoluminescence using ECL as substrate for the horseradish peroxidase (Amersham, Braunschweig, Germany).
